Standard‐Dose Versus High‐Dose Cisplatin for Intermediate/Poor‐Risk Extracranial Malignant Germ Cell Tumors: Re‐Analysis of Pediatric Oncology Group 9049 and Children's Cancer Group 8882 Trial Using Updated MaGIC Risk Stratification
Prior D, Yang J, Nuño M, Shaikh F, Frazier A, Pashankar F. Standard‐Dose Versus High‐Dose Cisplatin for Intermediate/Poor‐Risk Extracranial Malignant Germ Cell Tumors: Re‐Analysis of Pediatric Oncology Group 9049 and Children's Cancer Group 8882 Trial Using Updated MaGIC Risk Stratification. Pediatric Blood & Cancer 2025, 72: e31665. PMID: 40098231, PMCID: PMC12018124, DOI: 10.1002/pbc.31665.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCisplatinClinical Trials, Phase II as TopicEtoposideFemaleFollow-Up StudiesHumansMaleMediastinal NeoplasmsMulticenter Studies as TopicNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsPrognosisRetroperitoneal NeoplasmsRisk AssessmentSecondary Data AnalysisSurvival RateTesticular NeoplasmsConceptsGerm cell tumorsEvent-free survivalOverall survivalStandard of careRisk stratificationCell tumorsExtracranial malignant germ cell tumorsHigh-risk germ cell tumorsMalignant Germ Cell International ConsortiumRetroperitoneal germ cell tumorsOvarian germ cell tumorsMalignant germ cell tumorsHigh-dose cisplatinChildren's Cancer GroupYears of ageStatistically significant differenceMediastinal primaryGCT patientsIntergroup trialPoor riskHDPEBHigh-doseRandomized patientsAdolescent patientsPoor prognosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply